

Making Manual Plasmid Mini-Preps a Thing of the Past.

High Purity
 Sufficient for automated,
 fluorescent and maural
 setmenting

Be that as it may, Duesberg's rejoinders to all objections reminded me of the old story of the man who complained to a psychiatrist that he thought he was dead. The psychiatrist then asked whether dead men bleed, and on receiving a negative answer, took out a lancet and stuck the patient's finger. The man stared at his bleeding finger for a moment and then said, "Well, I guess dead men do bleed."

Stanley A. Plotkin
Medical and Scientific Director,
Pasteur Merieux Serums et Vaccins,
3, Avenue Pasteur,
Boite Postale 10,
92430 Marnes-la-Coquette, France

Response: I find Peter Duesberg's letter confusing. The mainstream view of AIDS is that HIV debilitates the immune system, allowing pathogens that are usually quite feeble to cause severe disease and even death. I don't see how the finding that a newly discovered herpesvirus may cause KS challenges the mainstream view. The role of HIV is highlighted by the fact that KS, in the absence of immunosuppression, is almost always a benign disease, but in AIDS patients it is often fatal.

On a separate point, Nicholas Birkett correctly notes that the Concorde data, like any scientific data, can be interpreted in more than one way. But Birkett does not emphasize just how slight the differences were in the Concorde trial between the HIV-infected people who were treated early with AZT and those who were untreated or received deferred treatment. As shown in a table accompanying the story, the P values—a measure of statistical significance—were 0.13 for total deaths and 0.34 for HIV-related deaths. Those are far from the P value 0.05 that most researchers accept as the minimal cutoff point for statistical significance.

Therefore, while it is true to say—as Duesberg does—that there is a 25% difference between the total deaths in the two groups, how much significance can be imputed to that figure remains an open question. In my article, I reported the view of the chief French Concorde researcher, who argues that the Concorde data do not support Duesberg's contention that AZT causes AIDS. Instead, as the Concorde study team concluded, the data simply indicate that treatment with AZT does not benefit healthy, HIV-infected people.—Jon Cohen

Chromosome Behavior in Mutants Defective in DNA Methylation: Correction

In our report describing the isolation of *Neurospora* mutants defective in DNA methyl-

ation, "Abnormal chromosome behavior in Neurospora mutants defective in DNA methylation" (10 Dec. 1993, p. 1737) (1), we reported evidence for aneuploidy in a mutant (dim-2) devoid of detectable methylation. We also reported that mutants with defects in the biosynthetic pathway leading to the methyl group donor S-adenosylmethionine can be manipulated to show reduced methylation, and we used one such mutant, met-7, to follow up the suggestion that reduction in methylation leads to the abnormal chromosome behavior. A large fraction of progeny from crosses between two met-7 strains showed evidence of aneuploidy, supporting the notion that normal DNA methylation is required for proper chromosome behavior. Results of recent experiments in our laboratory indicate, however, that our source of the met-7 mutation, FGSC strain 3915, contains a previously unrecognized recessive mutation, unrelated to met-7, that is responsible for the unusual chromosome behavior (2). In addition, attempts to quantify the effect of dim-2 on an euploidy did not show significant increases in aneuploidy attributable to dim-2 (3). Thus, we wish to retract our interpretation that methylation deficiencies cause abnormal chromosome behavior. Finally, we wish to correct an error in the legend to figure 6: the met-7 strain number should have read "N561 (FGSC 4143)" instead of "N556 (FGSC 3915)."

Henriette M. Foss Christopher J. Roberts Karen M. Claeys\* Eric U. Selker Institute of Molecular Biology, University of Oregon, Eugene, OR 97403, USA

## References

- H. M. Foss, C. J. Roberts, K. M. Claeys, E. U. Selker, Science 262, 1737 (1993).
- A. Hagemann, J. Irelan, H. Foss, C. Roberts, E. Selker, unpublished data.
- 3. A. Hagemann and E. Selker, unpublished data.

\*Present address: Department of Radiation Oncology, University of Washington Medical Center, Seattle, WA 98195, USA.

## **Sequence Correction**

We wish to note a correction of the NPM-ALK sequence (GenBank accession number U04946) described in our report "Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma" (4 March 1994, p. 1281) (1). After re-examination of our sequencing data, we identified an erroneous omission of two nucleotides in the codon of NPM-ALK amino acid residue 495 that was made because of a reading error. The frame-shift produced by this error led us to assign a premature termi-